Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 12/20 | 0.59 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 12/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952743 | 0.82 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| SCHEMBL952920 | 0.80 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL952798 | 0.79 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| SCHEMBL5827514 | 0.77 | ADRA2A (0.57) | ADRA2AADRA2BADRA2C | |
| SCHEMBL272384 | 0.74 | CYP3A4 (0.52) | ADRA2AADRA2CSLC6A4ADRA1AKCNH2 | |
| SCHEMBL953104 | 0.74 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| SCHEMBL953868 | 0.72 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Hydrochloric Acid SCHEMBL953120 | 0.72 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 | |
| SCHEMBL955429 | 0.72 | MAOA (0.62) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL8807072 | 0.72 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026357-B2 | Diphenylurea compounds | LES LABORATOIRES SERVIER (FR) | 2006-04-11 | — | — | US | disclosed |
| EP-1170288-B9 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2005-01-26 | — | — | EP | disclosed |
| US-20040224993-A1 | Diphenylurea compounds | LAVIELLE GILBERT (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6784183-B2 | ANTISEROTONINE AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-08-31 | — | — | US | disclosed |
| EP-1170288-B1 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | SERVIER LAB (FR) | 2004-08-11 | — | — | EP | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | ADRA2A 50/4885ADRA2B 98/4885ADRA2C 25/4885 |
| US-20040224993-A1 | Diphenylurea compounds | HTR2C, HTR2A, HTR1A | ADRA2A 38/4885ADRA2B 45/4885ADRA2C 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.